Physician profile
Larry E Carter
NPI 1285954669
$2,308.97
in general payments reported to CMS, 2019-2025
30 companies · $554 in 2025
The $554 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $347 · 2020: $90.44 · 2021: $23.56 · 2022: $243 · 2023: $344 · 2024: $708 · 2025: $554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,605.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,605.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $842.57 | 2019-2025 | Rinvoq, Viberzi, Linzess |
| Celltrion USA INC. | $210.27 | 2024-2025 | Vegzelma |
| Janssen Biotech, INC. | $189.21 | 2022-2024 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $134.54 | 2024-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $105.55 | 2020-2025 | Trulance, Xifaxan |
| Pfizer INC. | $78.65 | 2019-2025 | |
| Redhill Biopharma INC. | $69.44 | 2023-2024 | Talicia, Aemcolo, Movantik |
| Ipsen Biopharmaceuticals, INC | $58.68 | 2025 | Iqirvo |
| Gilead Sciences, INC. | $54.15 | 2023-2024 | |
| Paratek Pharmaceuticals, INC. | $53.89 | 2024-2025 | Nuzyra |
| Intercept Pharmaceuticals, INC. | $47.00 | 2022-2025 | Ocaliva |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.67 | 2022-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $35.76 | 2023 | Jynarque |
| Ferring Pharmaceuticals INC. | $35.44 | 2023 | Rebyota |
| Lilly USA, LLC | $34.19 | 2023-2025 | Mounjaro, Jardiance, Emgality |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $32.95 | 2020-2025 | Wegovy |
| Nestle Healthcare Nutrition INC. | $30.00 | 2023 | |
| Ardelyx, INC. | $29.04 | 2024 | Ibsrela |
| Ethicon US, LLC | $23.63 | 2023 | Dermabond |
| Philips North America LLC | $23.38 | 2024 | (5044) Mcot |
| Neurocrine Biosciences, INC. | $21.98 | 2025 | |
| Kyowa Kirin, INC. | $21.48 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $20.25 | 2024 | Dupixent |
| Pharmacosmos Therapeutics INC. | $18.84 | 2024 | Monoferric |
| Genzyme Corporation | $18.56 | 2022 | |
| Organon LLC | $17.05 | 2023 | Hadlima, Renflexis |
| Amgen INC. | $16.57 | 2024 | Tezspire |
| Biogen, INC. | $16.23 | 2025 | Tysabri, Vumerity |
| Shield Therapeutics INC | $14.95 | 2024 | |
| Celgene Corporation | $14.05 | 2023 | Zeposia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.